Cardiac safe, rapid medication delivery
First Claim
Patent Images
1. A method of identifying a cardiovascular safe dose of a drug active agent for delivery by inhalation, the method comprising:
- (a) determining a peak arterial concentration of the drug active agent following (i) inhalation delivery of the drug active agent, and (ii) intravenous delivery of the drug active agent, (b) identifying a cardiovascular safe intravenous dose of the drug active agent based on cardiovascular safety measurements taken after intravenous delivery of the drug active agent; and
(c) defining a cardiovascular safe inhaled dose of the drug active agent as less than or equal to the cardiovascular safe intravenous dose divided by the ratio of the peak drug active agent concentration produced by the inhalation delivery relative to that produced by the intravenous delivery.
2 Assignments
0 Petitions
Accused Products
Abstract
The disclosure provides methods and compositions for providing an effective dose of an active agent and/or drug composition to a subject by inhalation. The methods of the disclosure are useful in determining a maximal effective dose that limits cardiovascular damage upon inhalation.
115 Citations
12 Claims
-
1. A method of identifying a cardiovascular safe dose of a drug active agent for delivery by inhalation, the method comprising:
-
(a) determining a peak arterial concentration of the drug active agent following (i) inhalation delivery of the drug active agent, and (ii) intravenous delivery of the drug active agent, (b) identifying a cardiovascular safe intravenous dose of the drug active agent based on cardiovascular safety measurements taken after intravenous delivery of the drug active agent; and
(c) defining a cardiovascular safe inhaled dose of the drug active agent as less than or equal to the cardiovascular safe intravenous dose divided by the ratio of the peak drug active agent concentration produced by the inhalation delivery relative to that produced by the intravenous delivery. - View Dependent Claims (5, 6, 7, 8, 9)
-
-
2. A method of identifying a cardiovascular safe dose of a drug active agent for systemic delivery by inhalation, the method comprising:
-
(a) determining a rate of absorption of the drug active agent into the arterial circulation by inhalation delivery, and (b) determining the cardiovascular safety of the drug active agent delivered at a substantially identical rate at one or more doses by intravenous delivery, wherein the cardiovascular safe dose of the inhaled active agent is equal to or less than the dose that is determined to be safe when delivered at a substantially identical rate by the intravenous delivery.
-
-
3. An aerosol-releasing device for inhalation therapy, wherein the device releases one or more doses of aerosol that, when inhaled by a mammal, results in a spike index of between about 1.5 and 10, wherein the spike index is determined by:
-
(a) administering to a subject an equal amount of a drug active agent by both inhalation delivery and intravenous delivery;
(b) identifying an inhaled peak arterial plasma concentration after delivery of drug active agent in an aerosol by inhalation;
(c) identifying an intravenous peak arterial plasma concentration after delivery of a substantially identical dose of the drug active agent by IV injection; and
(d) dividing the inhaled peak arterial plasma concentration by the intravenous peak arterial plasma concentration to determine the spike index.
-
-
4. A method of delivering a drug active agent to a mammal, the method comprising administering the drug active agent by inhalation in the form of an aerosol, wherein the administration produces a spike index between 2 and 6, and wherein the peak left ventricular plasma concentration of the drug active agent is achieved in less than 30 seconds.
-
10. A method of delivering a heat stable drug active agent to a mammal to achieve a rapid therapeutic effect, the method comprising
generating an aerosol of the drug active agent, and delivering the aerosol into the pulmonary tract of the mammal to produce a peak arterial plasma concentration, wherein the peak plasma concentration is achieved more rapidly than following intravenous bolus delivery of the same medication.
-
12. A method of delivering a heat stable drug active agent to a mammal, the method comprising
generating an aerosol of the medication, and delivering the aerosol into the pulmonary tract of the mammal to produce (a) a peak arterial plasma concentration and (b) a peak venous plasma concentration, wherein the peak arterial plasma concentration is between 2 and 10 times greater than the peak venous plasma concentration.
Specification